glp-1 receptor agonist drugs in development research Advances agonists: Molecular mechanisms, drug delivery innovations, formulation strategies, and emerging therapeutic applications GLP-1 Receptor Agonists as Treatments

Research Base Comparison Both compounds have substantial published research bases: AOD-9604

CO-50 (medical necessity not met) fires when the payer determines the service wasn't medically necessary based on the submitted diagnosis

All tirzepatide doses were more efficacious than GLP-1 RAs in achieving a body weight loss of at least 10% and 15% (ESM Table 2)

In a double-blind, placebo-controlled study lasting 17 weeks, 18 healthy sedentary men aged 60-71 were randomised to one of two treatment rgimes: a placebo tablet twice a day or 1,000mgs of acetyl L-carnitine (ALC) and 400mgs of alpha lipoic acid (ALA) in two divided doses

It is legally sold for research purposes only and is not permitted in dietary supplements or as a prescription medication